Hereditary Colorectal Cancer Beyond Lynch Syndrome: Understanding the Polyposis Syndromes

By Amanda Shrewsbury, MS, CGC

When people think about hereditary causes of colon cancer, Lynch syndrome is often the first and only thing that comes to mind. However, there is a whole group of inherited conditions that is associated with increased risk of colon cancer due to colon polyps (and can be associated with other cancer risks, too).

These are the hereditary polyposis syndromes, and they work differently than Lynch syndrome does. They present mainly with colon polyps, sometimes a handful and sometimes hundreds, and the number, the type, and the age at which they appear are all significant pieces of information. Several of them also carry risks well beyond the colon, which is part of why recognizing them matters so much.

This post covers what the polyposis syndromes are, how they differ from Lynch syndrome, how many polyps may suggest a genetic cause, and the four syndromes that come up most often. It is written for anyone who has had polyps and wondered what they mean, anyone with a family history of polyps or colorectal cancer, and anyone already living with one of these diagnoses who wants a clearer picture.

What are hereditary polyposis syndromes?

Hereditary polyposis syndromes are inherited conditions in which a person develops multiple polyps in the gastrointestinal tract, usually the colon, and carries an elevated risk of colorectal cancer as a result.

Roughly 5 to 10 percent of colorectal cancers are attributed to well-defined hereditary syndromes, a group that includes Lynch syndrome, the adenomatous polyposis syndromes such as familial adenomatous polyposis and MUTYH-associated polyposis, and the hamartomatous polyposis syndromes such as juvenile polyposis syndrome and Peutz-Jeghers syndrome.

Certain kinds of polyps can develop into cancer over time, and someone with a polyposis syndrome develops far more of them, often much earlier, than someone without one. Each additional polyp represents another opportunity for that process to begin, which is why surveillance and removal are so central to management.

How is a polyposis syndrome different from Lynch syndrome?

The clearest difference is that polyposis syndromes are defined by polyp burden and Lynch syndrome is not.

Lynch syndrome is caused by a pathogenic variant (a DNA change that increases cancer risk) in one of the mismatch repair genes, and people with Lynch syndrome do not typically develop large numbers of polyps. Their cancer risk comes from how quickly an individual polyp can progress, not from having many of them. That is why colonoscopy for someone with Lynch syndrome is recommended frequently, often every one to two years, since the window between a polyp appearing and becoming a problem can be short.

Polyposis syndromes work differently. The defining feature is the polyps themselves, and management centers on tracking and removing them, sometimes to the point where surgery becomes the better option. Our post on Lynch syndrome covers that condition in depth, and this post is the companion piece for everything else.

How many colon polyps suggest a genetic cause?

For adenomas, the polyp type most associated with colorectal cancer risk, the National Comprehensive Cancer Network recommends genetic testing for an adenomatous polyposis syndrome in anyone with 20 or more cumulative adenomas, and recommends considering testing in those with 10 to 19 cumulative adenomas. Separately, NCCN's colorectal cancer screening algorithm advises that finding 10 or more adenomas and/or sessile serrated polyps in a single colonoscopy, or 10 or more accumulated over time, should prompt consideration of a polyposis syndrome and referral for genetic evaluation, though serrated lesions themselves are assessed under distinct serrated polyposis syndrome criteria rather than counted toward the adenoma thresholds. The American College of Gastroenterology has similarly recommended genetic evaluation for individuals with more than 10 cumulative colorectal adenomas.

For hamartomatous polyps, which are a different type, the threshold is much lower. The US Multi-Society Task Force on Colorectal Cancer recommends genetic evaluation for anyone with two or more lifetime hamartomatous polyps, a family history of hamartomatous polyps, or a first- or second-degree relative with a cancer associated with a hamartomatous polyposis syndrome, with testing (when indicated) performed using a multigene panel (Boland et al., 2022).

A few things are worth knowing about these numbers. They are cumulative, meaning polyps are counted across multiple colonoscopies over the years, not just one procedure. The type of polyp also matters, which is why your pathology reports are useful to hold onto. And these are thresholds for considering genetic evaluation, not diagnoses in themselves. Plenty of people who meet them do not turn out to have a hereditary syndrome.

What is familial adenomatous polyposis?

Familial adenomatous polyposis, usually shortened to FAP, is the most recognized adenomatous polyposis syndrome. It is caused by pathogenic variants in the APC gene and is inherited in an autosomal dominant pattern, meaning a child of someone with FAP has a 50 percent chance of inheriting the variant.

In its classic form, FAP involves hundreds to thousands of adenomatous polyps throughout the colon and rectum, with polyps often beginning to appear in the early teenage years. Without treatment, the lifetime risk of colorectal cancer approaches 100 percent, typically by around age 40. This is why management is proactive rather than watchful, and why most people with classic FAP eventually have surgery to remove the colon, often somewhere between the late teens and early thirties.

There is also an attenuated form, called AFAP, which is less aggressive. It generally involves fewer adenomas, in the range of 10 to under 100, with onset roughly 10 to 20 years later than classic FAP. The colorectal cancer risk is still substantial without intervention, but the timeline and the management look different.

FAP also carries risks outside the colon. These can include cancers of the duodenum and small bowel, papillary thyroid cancer, pancreatic cancer, hepatoblastoma in early childhood, and stomach cancer, along with non-cancerous findings such as desmoid tumors and characteristic changes in the retina. Upper gastrointestinal surveillance is an important part of care even after colon surgery.

What is MUTYH-associated polyposis?

MUTYH-associated polyposis, or MAP, somewhat resembles attenuated FAP clinically but is inherited differently, and that difference matters a great deal for families.

MAP occurs when a person inherits two pathogenic MUTYH variants, one from each parent. This is autosomal recessive inheritance, which is unusual among hereditary cancer syndromes and often surprising to families, because it means both parents are typically carriers of a single variant without having the condition themselves. People with MAP generally develop fewer than 100 adenomas, often appearing later than in classic FAP, and carry a substantially elevated risk of colorectal cancer. Associated risks outside the colon can include duodenal, ovarian, bladder, and skin cancers.

Because MUTYH involves recessive inheritance, it has implications for family planning in a way that most hereditary cancer genes do not. Our post on hereditary cancer variants and family planning covers the carrier side of MUTYH and why testing a partner or donor can matter.

What is Peutz-Jeghers syndrome?

Peutz-Jeghers syndrome is caused by pathogenic variants in the STK11 gene and is inherited in an autosomal dominant pattern. It involves a different kind of polyp, called hamartomatous polyps, which develop throughout the gastrointestinal tract and most commonly in the small bowel.

Peutz-Jeghers syndrome has a distinctive feature that often shows up long before any polyp does: dark pigmented spots on the lips, around the mouth, and sometimes on the fingers, around the eyes, or in other locations. These typically appear in early childhood and often fade during adolescence and adulthood (which can sometimes make initial diagnosis challenging).

Management involves two separate concerns. The first is mechanical, since polyps in the small bowel can cause bleeding or intussusception, a form of bowel obstruction that can require emergency surgery. Endoscopic surveillance and polyp removal help reduce that risk. The second is cancer risk, which is broad. Peutz-Jeghers syndrome is associated with elevated risks of gastrointestinal cancers including colorectal, gastric, small bowel, and pancreatic cancer, along with breast, ovarian, cervical, uterine, testicular, and lung cancers (Boland et al., 2022). Because the risks span so many organs, care is multidisciplinary.

What is juvenile polyposis syndrome?

Juvenile polyposis syndrome is caused by pathogenic variants in either the SMAD4 or BMPR1A gene, inherited in an autosomal dominant pattern. The word juvenile here describes the type of polyp under the microscope, not the age of the person, which is a common point of confusion. People with juvenile polyposis syndrome develop juvenile polyps in the gastrointestinal tract and carry elevated risks of colorectal and gastric cancer.

Which gene is involved changes the clinical picture meaningfully. SMAD4 pathogenic variants can also cause hereditary hemorrhagic telangiectasia, a separate vascular condition affecting blood vessels, so people with a SMAD4 variant need evaluation and management for that as well. This overlap is one reason genetic testing, rather than a clinical diagnosis alone, is so valuable here.

Do these syndromes affect anything besides the colon?

Yes, and this is one of the most important things to take away.

Every syndrome above carries risks beyond the colon: upper gastrointestinal, thyroid, and other cancers in FAP; duodenal, ovarian, bladder, and skin in MAP; a wide multi-organ spectrum in Peutz-Jeghers; gastric cancer and the vascular condition associated with SMAD4 in juvenile polyposis. A diagnosis shapes far more than colonoscopy timing. It shapes which other screenings a person needs, which specialists are involved, and what relatives should be evaluated for.

Are there other polyposis syndromes?

There are, and they are rarer. These include NTHL1-associated polyposis and polymerase proofreading-associated polyposis (involving the POLE and POLD1 genes), both of which have been described relatively recently, as well as PTEN hamartoma tumor syndrome, which includes Cowden syndrome, and serrated polyposis syndrome. Because these conditions can look similar to one another, current guidelines recommend multigene panel testing rather than testing one gene at a time, so that the evaluation can distinguish among them.

Should children be tested for a polyposis syndrome?

Usually genetic testing is deferred until adulthood, when results can guide a person's own decisions. However, the polyposis syndromes are one of the clearest exceptions to that default, where testing is recommended in childhood.

When FAP is known or suspected in a family, testing before age 18 is recommended, because surveillance itself begins in childhood. For a child with an APC variant, colonoscopy is generally recommended annually beginning around ages 10 to 15. Juvenile polyposis syndrome and PTEN hamartoma tumor syndrome are also recognized exceptions where earlier testing is appropriate, since results change medical management during childhood. For families with a SMAD4 variant specifically, evaluation of at-risk relatives is recommended very early because of the associated vascular condition.

This is not a reason for alarm so much as a reason for planning. The exception exists precisely because early knowledge allows early protection. Our post on the right age for genetic testing covers how these decisions are approached more generally.

What if you have already been diagnosed?

If you are reading this after a colorectal cancer diagnosis, or while already living with a polyposis syndrome, this information still has a place.

A genetic diagnosis can clarify your own care going forward, including which additional screenings make sense and what your risk of another cancer looks like. It can explain a family history that never quite made sense. And it gives your relatives something concrete to act on, since a confirmed variant in the family allows targeted testing that is far more informative than starting from scratch. Our post on genetic testing after a cancer diagnosis covers more of what a result can mean when you are already in treatment.

If you have been living with a polyposis diagnosis for years, it may also be worth revisiting. Genetic testing has changed considerably, and some people diagnosed clinically before comprehensive panel testing was available may have a genetic variant that wasn't previously identifiable.

What to do next

If your polyp history or your family's has raised questions, a genetic counselor can help you sort out whether an evaluation makes sense. That conversation involves reviewing your polyp counts and pathology, mapping your family history, and determining whether testing is likely to be informative for you.

A few resources from our blog that may help:

Frequently Asked Questions

Does having colon polyps mean I have a hereditary syndrome?

Usually not. Colon polyps are common, and most are not caused by an inherited condition. What raises the question is the number of polyps, the type, the age at which they appeared, and whether other family members have had polyps or colorectal cancer.

Can a polyposis syndrome be diagnosed without genetic testing?

Some can be diagnosed clinically based on polyp count, polyp type, and family history. Genetic testing is still valuable, because identifying the specific gene refines management, clarifies which non-colon screenings are needed, and allows relatives to be tested accurately.

If my genetic testing did not find a variant, does that rule out a hereditary syndrome?

Not entirely. Some people meet the clinical criteria for a polyposis syndrome without an identifiable variant, and in those cases surveillance is still guided by the clinical picture. Our post on uninformative negative results explains this situation in more detail.

Do I need a colonoscopy earlier if a parent had a polyposis syndrome?

Very likely, and the specifics depend on which syndrome and which gene. Screening for these conditions generally begins considerably earlier than standard colorectal cancer screening, and in some cases during childhood. A genetic counselor and your gastroenterologist can determine the right timing for you.

One last thought

If you or your family's colon polyp history is enough to make you wonder if it's hereditary, it's absolutely worth bringing up to your care team and seeing a genetic counselor. Colon polyp history can be a significant clue to something hereditary, and can have a huge impact on you and your family members.

---

Talk with a ClearPath Genetic Counselor

If you have a personal or family history of colon polyps or colorectal cancer and want to understand whether a hereditary syndrome may be involved, we can help.

Have a Question? Text or call us at (720) 799-0730 or email us at hello@clearpathgenetics.com.

---

References

Boland, C. R., Idos, G. E., Durno, C., Giardiello, F. M., Anderson, J. C., Burke, C. A., Dominitz, J. A., Gross, S., Gupta, S., Jacobson, B. C., Patel, S. G., Shaukat, A., Syngal, S., & Robertson, D. J. (2022). Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes: Recommendations from the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 162(7), 2063–2085.

Facing Our Risk of Cancer Empowered (FORCE). (2026). Hereditary colorectal cancer syndromes and risk management. https://www.facingourrisk.org/

National Comprehensive Cancer Network. (2026). NCCN clinical practice guidelines in oncology: Genetic/familial high-risk assessment — Colorectal, endometrial, and gastric (Version 1.2026). https://www.nccn.org/

National Comprehensive Cancer Network. (2026). NCCN clinical practice guidelines in oncology: Colorectal cancer screening (Version 1.2026). https://www.nccn.org/

---

This blog post is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician, genetic counselor, or other qualified healthcare provider with any questions you may have regarding a medical condition or your individual health needs.